Introduction {#s1}
============

The present article addresses the management of patients with advanced pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) and right-sided heart failure, focusing on intensive care, use of extracorporeal life support (ECLS) and lung transplantation. Other causes of right-sided heart failure as seen for instance in patients with acute pulmonary embolism, right ventricular infarction or right-sided heart failure secondary to left-sided heart failure will not be discussed here.

The following definitions of right-sided heart failure will be used: 1) Right-sided heart failure is characterised by low cardiac output and/or elevated right-sided filling pressures due to systolic and/or diastolic right ventricular dysfunction.2) Right-sided heart failure is severe if it leads to secondary dysfunction of other organs and tissues, in particular liver, kidneys and gut.This article addresses topics where robust data from large clinical trials are not available. Hence, most of the statements and recommendations are based on clinical experience and expert consensus rather than scientific evidence.

Pathophysiology of right-sided heart failure {#s2}
============================================

The pathophysiology of right-sided heart failure has been described in depth elsewhere \[[@C1]--[@C3]\]. Here, only a couple of points will be highlighted that are considered of importance for treatment considerations.

Like left-sided heart failure, right-sided heart failure may present as isolated systolic heart failure or isolated diastolic heart failure; however, combined forms are frequently encountered in patients requiring treatment on the intensive care unit (ICU). Systolic right-sided heart failure results in left ventricular underfilling and low cardiac output, which impairs tissue perfusion and oxygenation. Diastolic right-sided heart failure results in elevated systemic venous pressure with detrimental consequences for tissue perfusion and oxygenation as well.

With increasing afterload, the right ventricle remodels, *i.e.* hypertrophies and eventually dilates, developing a spherical shape accompanied by increased right ventricular wall stress, impaired myocardial contractility and progressive tricuspid regurgitation, which further reduces effective cardiac output. Ventricular interdependence results in impaired left ventricular filling and function.

Severe right-sided heart failure affects all organ systems; in the ICU setting, the consequences for the liver, kidneys and gut are often most relevant. Several lines of evidence suggest that elevated venous pressures with chronic congestion are particularly damaging to these organs \[[@C4]--[@C9]\]. Malperfusion and congestion alter bowel wall permeability, and may cause translocation of bacteria and endotoxins from the bowel into the circulation resulting in a systemic inflammatory response or sepsis \[[@C4], [@C10], [@C11]\], which are common contributors to death in patients with right-sided heart failure \[[@C12]\].

Symptoms and signs of right-sided heart failure {#s3}
===============================================

Symptoms and signs of low cardiac output failure can be subtle. Tachycardia is often present, while systemic hypotension usually develops only at advanced stages. The skin may have a pale appearance; cyanosis may be present but is not obligate. Patients frequently complain about fatigue and appear tired. Agitation may be present as well and may signal imminent death. The clinical signs of right-sided backward failure such as prominent and pulsating jugular veins, ascites, and oedema are usually obvious.

Principles of ICU monitoring of patients with right-sided heart failure {#s4}
=======================================================================

ICU monitoring of patients with PH/PAH and right-sided heart failure should focus on cardiac function and the function of other organs ([table 1](#TB1){ref-type="table"}).

###### 

Intensive care unit (ICU) monitoring of patients with right-sided heart failure

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tools**                                                                               **Information provided**
  ----------------------------------------------- --------------------------------------------------------------------------------------------------------
  **Basic ICU monitoring**                                                                 Heart rate and rhythm

                                                                                 Blood pressure (non-invasive or invasive)

                                                                                              Body temperature

                                                                            Peripheral oxygen saturation or arterial blood gases

                                                                                    Urine output, changes in body weight

  **Central venous catheter**                                                             Central venous pressure

                                                                                      Central venous oxygen saturation

  **Laboratory values**                              Cardiac biomarkers (N-terminal pro-brain natriuretic peptide/brain natriuretic peptide, troponin)

                                                   Electrolytes and renal function (estimated glomerular filtration rate, blood urea nitrogen, uric acid)

                                                                               Liver function (aminotransferases, bilirubin)

                                                                         Inflammation/infection (C-reactive protein, procalcitonin)

                                                                              Tissue damage or hypoxia (blood gases, lactate)

  **Echocardiography**                                            Right and left ventricle function, valve function, pericardial effusion

                                                        Rule out other conditions mimicking right ventricular failure, such as pericardial tamponade

  **Right heart catheterisation (facultative)**                                    Comprehensive haemodynamic assessment\
                                                                              To be considered in severe or complex situations
  --------------------------------------------------------------------------------------------------------------------------------------------------------

In patients requiring ICU treatment, monitoring of cardiac function is essential. Right heart catheterisation, preferably with continuous cardiac output measurement, is not always necessary, but should be considered in severe and complex cases. Other tools to measure cardiac output should be considered as well.

Insertion of a central venous line is considered mandatory in patients requiring ICU treatment for right-sided heart failure. Central venous pressure measurement, which has been abandoned in most ICU patients due to poor correlation with fluid status, is pivotal in patients with right ventricular failure to determine right-sided filling pressures, keeping in mind the detrimental effects of elevated filling pressures (see earlier). In addition, central venous oxygen saturation (*S*~cvO~2~~) measurements are important to determine tissue oxygenation as *S*~cvO~2~~ correlates with cardiac output \[[@C13]\].

Recommendations for ICU monitoring of patients with PH and severe right-sided heart failure {#s4a}
-------------------------------------------------------------------------------------------

-   ICU monitoring of patients with severe right-sided heart failure should include regular measurements of central venous pressure and *S*~cvO~2~~.

-   Key warning signs of imminent death in patients with right-sided heart failure are a decline in *S*~cvO~2~~ accompanied by an increase in lactate and a decline in urine output.

-   The use of right heart catheterisation or other devices to monitor haemodynamics and cardiac output should be considered in patients with severe right-sided heart failure and in complex situations.

ICU treatment of severe right-sided heart failure {#s5}
=================================================

Patients with severe right-sided heart failure require comprehensive care including treatment of factors causing or contributing to heart failure, fluid management and strategies to improve cardiac function ([figure 1](#F1){ref-type="fig"}). If possible, such patients should be treated at expert centres capable of providing all treatment options, *i.e.* medical therapy, ECLS and lung transplantation. Interhospital transfer must be considered on an individual basis. Some centres provide mobile units facilitating interhospital transfer with ECLS \[[@C14]\].

![Therapeutic approach to patients with severe right-sided heart failure. RV: right ventricular; PAH: pulmonary arterial hypertension; NO: nitric oxide; ECMO: extracorporeal membrane oxygenation; ECLS: extracorporeal lung support. Reproduced and modified from \[[@C80]\] with permission.](ERJ-01906-2018.01){#F1}

Treatable precipitants of right-sided heart failure include infection, anaemia, thyroid dysfunction, pulmonary embolism, arrhythmia or non-adherence to prescribed medications. Supraventricular tachyarrhythmias, especially atrial flutter and atrial fibrillation, are common causes of right-sided heart failure in patients with severe PH \[[@C15]\] and rapid restoration of sinus rhythm should be attempted in such cases. Infection is another important contributor to death in patients with right-sided heart failure. If the source of infection is not obvious, broad-spectrum antibiotics should be considered bearing in mind that translocation from the bowel is a frequent cause of systemic inflammation and sepsis in patients with right-sided heart failure \[[@C10], [@C11]\].

Supplementary oxygen should be administered as needed to maintain peripheral oxygen saturations \>90%. Hypercapnic patients may benefit from non-invasive ventilation \[[@C16]\], although caution is necessary as even non-invasive ventilation may further impair right ventricular function \[[@C17]\]. Whenever possible, intubation and invasive mechanical ventilation should be avoided in patients with severe right heart failure, as the induction of general anaesthesia together with a further increase in right ventricular afterload carries a high risk of death in these patients. If intubation is unavoidable, maintaining a stable blood pressure is of key importance.

Fluid management is often critical in patients with right-sided heart failure. It is a common reflex among intensivists to administer fluids to patients with hypotension or shock. Only rarely are patients with right-sided heart failure fluid-depleted as well. Most of these patients have markedly elevated right-sided filling pressures and a low cardiac output. In these patients, fluid administration may further increase right-sided filling pressures and chamber dimensions, thereby aggravating the shift of the interventricular septum to the left and increasing tricuspid regurgitation \[[@C18]\], all resulting in further deterioration of left ventricular filling and function, as illustrated in [figure 2](#F2){ref-type="fig"}. In such patients, a negative fluid balance should be sought by using *i.v.* loop diuretics or even haemofiltration \[[@C19]\].

![Effects on volume changes on cardiac function in right-sided heart failure. RV: right ventricle; LV: left ventricle; RVEDP: right ventricular end-diastolic pressure; TR: tricuspid regurgitation; CO: cardiac output. Reproduced and modified from \[[@C80]\] with permission.](ERJ-01906-2018.02){#F2}

To reduce right ventricular afterload, all drugs approved for PAH may be considered in patients presenting with severe right-sided heart failure. Intravenous prostacyclin analogues (PCAs) are usually preferred because of their efficacy and a rapid onset of action. Initial triple combination therapy consisting of *i.v.* epoprostenol, oral phosphodiesterase type 5 inhibitors and endothelin receptor antagonists in patients with newly diagnosed PAH and right-sided heart failure has been reported with excellent short-term and mid-term results \[[@C20]\].

Patients with low cardiac output may initially require the use of inotropes, with dobutamine and milrinone being the most widely used agents in this setting. In animal models of right-sided heart failure, levosimendan appears more effective than dobutamine \[[@C21], [@C22]\], but reliable clinical data are lacking. Patients with a low systemic vascular resistance may need additional vasopressor treatment. Norepinephrine and vasopressin are the preferred agents. Vasopressin may be advantageous as it has pulmonary vasodilator effects \[[@C23], [@C24]\], but the clinical relevance of this property is unknown ([table 2](#TB2){ref-type="table"}).

###### 

Inotropes and vasopressors in clinical use to treat advanced right heart failure

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug**                      **Cardiac output**   **PVR**   **SVR**   **Tachycardia/**\   **Pre-clinical studies**                       **Clinical studies/**\
                                                                          **arrhythmia**                                                        **experience**
  ---------------------------- -------------------- --------- --------- ------------------- -------------------------- ----------------------------------------------------------------
  **Inotropes**                                                                                                        

   Dobutamine                                                                                                          

    \<5 µg·kg^−1^·min^−1^               ↑               ↘      → or ↘           + +                  + + + +                   Large clinical experience, haemodynamic studies

    5--15 µg·kg^−1^·min^−1^             ↑↑              →         ↘            + + +                                   

   Dopamine                                                                                                            

    2.5--5 µg·kg^−1^·min^−1^            ↑               ?        ↑↑                                    +/−                                    ↑ Renal blood flow

    \>5 µg·kg^−1^·min^−1^               ↑               ↑                      + + +                                   

   Milrinone                            ↑↑              ↘        ↘↘            + + +                   + +                              Group 2 PH case reports in PAH

   Levosimendan                         ↑↑              ↘        ↘↘             \+                     + +                              Group 2 PH case reports in PAH

   Epinephrine                          ↑↑              ↘        ↑↑            + + +                                    Effective, but risk of myocardial necrosis and lactic acidosis

  **Vasopressors**                                                                                                     

   Norepinephrine                       ↑            → or ↑      ↑↑             + +                    + +                                Large clinical experience

   Vasopressin (low doses)            → or ↑            ↘        ↑↑            + + +                   + +                               Limited clinical data in PAH
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; PH: pulmonary hypertension; PAH: pulmonary arterial hypertension.

Recommendations for ICU treatment of patients with severe right-sided heart failure {#s5a}
-----------------------------------------------------------------------------------

-   Patients with PAH or other forms of severe PH with right-sided heart failure requiring ICU therapy should be treated at expert centres capable of providing all treatment options, *i.e.* medical therapy, ECLS and advanced treatment including lung transplantation, if possible.

-   Interhospital transfer should be considered on an individual basis. Some centres provide mobile units facilitating interhospital transfer with ECLS.

-   ICU treatment of patients with right-sided heart failure should include treatment of underlying causes and comorbidities, supportive measures, meticulous fluid management, reduction of right ventricular afterload with drugs approved for PAH, and an individualised use of inotropes and vasopressors.

Mechanical support of the right heart {#s6}
=====================================

In patients with right-sided heart failure refractory to treatment, mechanical support should be considered in certain situations, *i.e.* in candidates for lung transplantation (bridge to transplant) and, occasionally, in patients with a treatable cause of right-sided heart failure or in hitherto treatment-naive patients (bridge to recovery).

Technical principles and features of mechanical right ventricular support {#s6a}
-------------------------------------------------------------------------

There are various devices and device configurations to support the right ventricle, and the list is constantly growing \[[@C25], [@C26]\]. At present, the most widely used techniques are peripheral veno-arterial extracorporeal membrane oxygenation (ECMO) and pumpless membrane oxygenators inserted between the pulmonary artery and the pulmonary veins or left atrium (PA-LA).

Peripheral ECMO support is usually established *via* the femoral vessels but upper body approaches have been used as well, the latter mostly to enable ambulation, which is not possible with lower body cannulation. The veno-arterial configuration ensures rapid and effective unloading of the right ventricle \[[@C27]\]. With residual pulmonary blood flow, an ECMO blood flow of 2.5--4 L·min^−1^ is usually adequate to maintain sufficient perfusion of the entire organism, while effectively unloading the right ventricle and avoiding an unnecessary increase in left ventricular afterload. Still, this configuration is characterised by opposing blood flows in the aorta, one coming from the left ventricle, the other from the ECMO system. The area where these two blood flows meet is called the ECMO watershed, which is clinically relevant mostly for differential oxygenation \[[@C28]\]. In patients with femoral veno-arterial ECMO support, the lower body is supplied by blood originating from the ECMO and the upper body by blood coming from the heart. The location of the watershed is variable, and depends on the respective pressures and flows in the two circuits. While lower body oxygenation is safely maintained by ECMO, upper body oxygenation can be impaired when the blood coming from the left heart carries a low oxygen content. This affects predominantly the brain and the heart itself. While brain oxygenation can be indirectly monitored by right forearm oxygenation, it is usually not possible to measure the oxygen content in the aortic bulb and the coronary arteries. Hence, monitoring of cardiac function by regular troponin measurements and echocardiography is mandatory.

With the PA-LA approach, a membrane oxygenator is placed between the pulmonary artery and the left atrium. In patients with PH, a pump is usually not required, at least when low-resistance membranes are being used \[[@C29], [@C30]\]. PA-LA insertion is more complex than ECMO support as it requires surgery *via* sternotomy or antero-lateral thoracotomy. In addition, patients with advanced right-sided heart failure often need temporary ECMO support prior to anaesthesia. The main advantages of the PA-LA approach are that 1) ambulation is feasible, 2) oxygen-enriched blood enters the left ventricle and thereby the entire systemic circulation, and 3) the pre-load of the left ventricle is increased, which helps "priming" for the haemodynamic situation after transplantation (see later).

Right ventricular assist devices {#s6b}
--------------------------------

There are sporadic reports on isolated right ventricular assist device (RVAD) support in PAH \[[@C31]\]. However, successful long-term use of RVADs in patients with PAH has not yet been reported. The role of this intervention is limited given the pathophysiology of PAH, which may include aggravation of pulmonary vascular remodelling, risk of pulmonary bleeding and induction of pulmonary oedema in patients with left ventricular diastolic dysfunction \[[@C32]--[@C34]\]. For these reasons, isolated RVAD support should be used with utmost care or not at all in these patients. Smaller-sized devices with good ability to control the pump flow in the pulmonary circulation may open new options in the future \[[@C35]\].

Indications for mechanical support of the right ventricle {#s6c}
---------------------------------------------------------

The only established option for the use of ECLS in patients with PH and right-sided heart failure is bridge to transplantation ([table 3](#TB3){ref-type="table"}) \[[@C36], [@C37]\]. Hence, ECLS should be considered 1) if conventional treatment strategies fail in patients who 2) have already been fully evaluated for lung transplantation, who 3) have a realistic chance of receiving a donor organ in a reasonable time frame and who 4) can still be expected to have a good outcome after transplantation \[[@C26]\]. If possible, ECMO should preferably be used in awake, non-intubated and spontaneously breathing patients, not only to avoid the risks and complications associated with general anaesthesia and intubation in patients with right-sided heart failure, but also to prevent the negative consequences of mechanical ventilation, such as ventilator-associated pneumonia, muscular deconditioning and critical care illness. The awake ECMO strategy has proven feasible, even with bridging times of several weeks \[[@C38]\], and has been associated with better outcomes than historical bridging strategies that included intubation and mechanical ventilation \[[@C14], [@C39], [@C40]\].

###### 

Summary of published data on outcomes of patients with pulmonary arterial hypertension bridged to lung transplant with the use of extracorporeal life support devices

  **First author \[ref.\]**                                 **Patients who received ECMO support**                **Patients bridged to transplant**                             **Patients discharged from hospital**
  -------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------
  **[de]{.smallcaps} P[errot]{.smallcaps} \[30\]**                  6 (4 PA-LA, 2 VA ECMO)                                    6/6 (100%)                                                       4/6 (66%)
  **F[uehner]{.smallcaps} \[39\]**                                     7 (all VA ECMO)                                         6/7 (86%)                                                       5/6 (71%)
  **H[oopes]{.smallcaps} \[73\]**                                      5 (all VA ECMO)                                        5/5 (100%)                                                      5/5 (100%)
  **L[ang]{.smallcaps} \[74\]**                                        4 (all VA ECMO)                                        4/4 (100%)                                                      4/4 (100%)
  **R[osenzweig]{.smallcaps} \[41\]**                                  6 (all VA ECMO)                     2/2 (100%); 4 received ECMO as bridge to recovery   2/2 (100%); 1/4 (25%) bridge to recovery patients survived for \>2 months
  **S[hafii]{.smallcaps} \[75\]**                                      3 (all VA ECMO)                                         2/3 (66%)                                                      2/2 (100%)
  **C[rotti]{.smallcaps} \[76\]**                                  4 (3 VA ECMO, 1 VV ECMO)                                   4/4 (100%)                                                       3/4 (75%)
  **H[oetzenecker]{.smallcaps} \[77\]**                            13 (9 PA-LA, 4 VA ECMO)                                    11/13 (85%)                                            7/11 (63%) survived at 1 year
  **S[avale]{.smallcaps} \[56\]**                                      13 (all VA ECMO)                                      13/13 (100%)                                                     8/13 (62%)
  **D[ellgren]{.smallcaps} \[78\]**                                    2 (both VA ECMO)                                       2/2 (100%)                                                       1/2 (50%)
  **G[lorion]{.smallcaps} \[79\]**                           18 (13 VA ECMO, 3 VV ECMO, 2 PA-LA)                              17/18 (94%)                                                     15/17 (88%)
  **Total**                                           81 (66 ECMO, 15 PA-LA); 77 as bridge to transplant                      72/77 (94%)                                                     56/72 (78%)

ECMO: extracorporeal membrane oxygenation; PA-LA: pulmonary artery to left atrium device; VA: veno-arterial; VV: veno-venous.

The use of ECLS in patients who have not been evaluated for transplantation should be avoided unless there is a reasonable perspective for recovery. This may be the case in previously stable patients with a reversible cause of right-sided heart failure (*e.g.* arrhythmia or infection) or in hitherto untreated or undertreated patients with newly diagnosed PAH. Case reports demonstrating success of this approach are, however, rare \[[@C14], [@C41]\].

### Recommendations for the use of ECLS in patients with PH and right-sided heart failure {#s6c1}

#### Indications and contraindications {#s6c1a}

-   Established indication: bridge to transplant in patients who have been fully evaluated and accepted for this procedure.

-   Potential indications in highly selected cases: -- bridge to transplant decision in potentially eligible patients who have not yet been fully evaluated;-- bridge to recovery in patients with untreated or undertreated PAH, or in patients with a reversible cause of right ventricular failure.

-   Contraindication: end-stage disease without a realistic chance for recovery or successful transplantation (futility).

#### Choice of ECLS {#s6c1b}

-   Veno-arterial ECMO and the PA-LA approach are currently the only established right ventricular support strategies, but there is rapid evolution in device technologies.

-   At present, veno-arterial ECMO is the most widely used ECLS strategy.

-   The PA-LA approach should be considered if the expected ECLS time is of longer duration or in children with small femoral arteries.

-   The choice of ECLS depends largely on centre experience.

#### Timing of ECLS {#s6c1c}

-   All forms of ECLS are associated with potentially life-threatening complications; hence, ECLS should be used only when less invasive treatment options have been exhausted.

-   ECLS should be initiated when the clinical course suggests that terminal right heart failure and/or secondary organ failure is imminent despite optimised medical therapy.

-   ECLS initiated in patients with advanced PH/PAH undergoing cardiopulmonary resuscitation for right-sided heart failure will rarely result in good outcomes.

#### ECLS and lung transplantation {#s6c1d}

-   ECLS is now an established strategy to bridge patients with right heart failure to lung transplantation.

-   Centres performing lung transplantation in patients with PAH should have an established ECLS programme.

Lung transplantation {#s7}
====================

The modern era of successful lung and heart--lung transplantation started in the early 1980s with patients suffering from PH \[[@C42]\]. Today, due to the introduction of effective therapies for PAH and chronic thromboembolic PH, lung transplantation is performed less frequently in patients with severe PH, but remains an important treatment option for patients with refractory disease.

When to refer and when to list patients for lung transplantation {#s7a}
----------------------------------------------------------------

### Referral to a transplant centre {#s7a1}

General recommendations for the selection of lung transplant candidates have been published elsewhere \[[@C37]\]. In patients with PAH, referral to a lung transplant centre should be considered early, *i.e.* whenever patients display an inadequate response to treatment and are not at low risk of death despite receiving oral combination therapy ([table 4](#TB4){ref-type="table"}). Early transplant referral is also recommended in patients who are suspected to suffer from disease variants responding poorly to medical therapy, such as pulmonary veno-occlusive disease. An early referral strategy ensures that patients have time to consider lung transplantation with all its consequences, and that centres can fully evaluate potential candidates and optimise their pre-transplant condition. In reality, patients with PAH are often referred in an advanced disease state or when they are rapidly deteriorating, which may prohibit a careful evaluation, thereby exposing them to unnecessary risks and sometimes effectively depriving them of a chance of receiving a donor organ. Early referral for transplant evaluation does not mean that patients are necessarily listed right away; a completed evaluation just allows optimal timing and rapid listing in case of clinical deterioration.

###### 

Specific criteria for lung transplant referral and listing in patients with pulmonary arterial hypertension (PAH)

  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  **Referral**   Potentially eligible patients for whom lung transplantation might be an option in case of treatment failure
                 ESC/ERS intermediate or high risk or REVEAL risk score \>7 on appropriate PAH medication
                 Progressive disease or recent hospitalisation for worsening of PAH
                 Need for *i.v.* or *s.c.* prostacyclin therapy
                 Known or suspected high-risk variants such as PVOD or PCH, scleroderma, large and progressive pulmonary artery aneurysms
                 Signs of secondary liver or kidney dysfunction due to PAH or other potentially life-threatening complications such as recurrent haemoptysis
  **Listing**    Patient has been fully evaluated and prepared for transplantation
                 ESC/ERS high risk or REVEAL risk score \>10 on appropriate PAH medication, usually including *i.v.* or *s.c.* prostacyclin analogues
                 Progressive hypoxaemia, especially in patients with PVOD or PCH
                 Progressive, but not end-stage, liver or kidney dysfunction due to PAH or life-threatening haemoptysis
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------

ESC: European Society of Cardiology; ERS: European Respiratory Society; REVEAL: Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary haemangiomatosis.

### Listing patients for lung transplantation {#s7a2}

Patients suffering from PAH should be listed for lung transplantation when they present with a high risk of death despite optimised medical therapy, which usually consists of combination therapy including *s.c.* or *i.v.* PCAs ([table 4](#TB4){ref-type="table"}). According to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) PH guidelines \[[@C43], [@C44]\], patients are classified as high risk when the estimated 1-year mortality exceeds 10%. Registry data suggest that the 1-year mortality rate of these patients is in fact \>20% \[[@C45], [@C46]\]. Thus, utilising risk stratification tools or scores (*i.e.* REVEAL (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) score ≥10) \[[@C47]\]) that denote high-risk individuals may be particularly useful in deciding when to refer a patient for evaluation. Since the 1-year mortality after lung transplantation for severe PH in experienced centres is currently around 10% \[[@C48], [@C49]\], a survival benefit can be expected for such patients.

Patients listed for lung transplantation benefit from pre-transplant rehabilitation programmes \[[@C50]\].

With the introduction of the lung allocation score (LAS), waiting list mortality has decreased and the odds of receiving a donor organ have increased for most major lung diseases, including PAH \[[@C51], [@C52]\]. Still, the LAS does not always adequately reflect disease severity in patients suffering from PAH \[[@C53]\]. In a multivariable analysis comparing mortality predicted by the LAS system to actual mortality in REVEAL, two additional variables were independently associated with increased mortality compared with the LAS: mean right atrial pressure ≥14 mmHg and 6-min walk distance ≤300 m \[[@C54]\]. These two factors, in addition to total bilirubin and cardiac index, were added to a modified LAS, released in February 2015 \[[@C55]\], which also reweighted weight, list urgency and post-transplant outcomes in favour of PAH. The effect of these changes on outcome should be forthcoming in the next several years.

In some countries, an "exceptional LAS" can be obtained for patients with severe PH \[[@C56]\]. Some other countries not using the LAS have successfully implemented high-priority programmes for these patients \[[@C57]\].

Transplant procedure, post-transplant care and outcomes {#s7b}
-------------------------------------------------------

Major progress has been made over the past years in lung transplantation for PAH. One of the most important innovations was the use of ECMO support during and after transplantation \[[@C58]\]. Meanwhile, the intra-operative use of ECMO has almost completely replaced the use of conventional cardiopulmonary bypass as it has been associated with a reduction of peri-operative complications including renal failure, a reduced need for transfusions of blood products and (in some, but not all, series) with better survival \[[@C49], [@C59]--[@C63]\]. In patients with PH and right-sided heart failure undergoing transplantation, veno-arterial ECMO is occasionally established prior to general anaesthesia to avoid haemodynamic instability.

A better understanding of the pathophysiological changes after transplantation for PH with adaptation of therapeutic strategies (*e.g.* achieving a negative fluid balance including use of haemofiltration when necessary and extended ECMO support) has substantially reduced the occurrence of early graft dysfunction, which was the major obstacle of post-transplant survival in these patients and the main reason why the early post-operative mortality was historically higher in patients undergoing lung transplantation for PAH than for most other end-stage lung diseases \[[@C64]\].

As already reported in 1999 \[[@C65]\], the main cause of primary graft dysfunction in these patients was not residual PH, but left ventricular failure \[[@C33]\]. However, the notion that the small and "unconditioned" left ventricles of patients with severe PH are prone to developing diastolic dysfunction when exposed to a normal or high pre-load after transplantation only recently came into a wider focus of interest \[[@C32], [@C33], [@C48]\]. Left ventricular dysfunction results in elevated left-sided filling pressures and pulmonary oedema, which tends to worsen whenever patients are awake and agitated. In the past, this has frequently led to a vicious cycle making it difficult, and sometimes impossible, to wean patients from the ventilator, thereby exposing them to the risks associated with prolonged mechanical ventilation and intensive care. To overcome this problem, several centres over many years have used combined heart and lung transplantation for patients with severe PH \[[@C66], [@C67]\]. Today, however, the post-operative prolongation of veno-arterial ECMO after transplantation effectively prevents primary graft dysfunction \[[@C48], [@C68]\]. Two different approaches have been described: 1) prolongation of ECMO with extubation first and continuation of ECMO support for 3--7 days \[[@C48]\] or 2) brief post-operative prolongation of ECMO in intubated patients until stabilisation of haemodynamics and normalisation of fluid balance followed by a few days of ventilation \[[@C49]\]. For both strategies, 1-year survival rates \>90% have been reported \[[@C48], [@C49]\]. There is now consensus among experts that bilateral lung transplantation is the procedure of choice for most patients with PAH. Of note, almost any right ventricle recovers within a few weeks after transplantation, regardless of the degree of pre-transplant dilatation and dysfunction, and regardless of the severity of pre-operative tricuspid regurgitation \[[@C69]--[@C71]\].

### Recommendations for lung transplantation in patients with PH/PAH {#s7b1}

-   Repeated risk assessment is pivotal to identify the appropriate time for initiating transplant evaluation.

-   Established and validated risk prediction tools such as the REVEAL risk score or the ESC/ERS risk prediction strategy should be applied in patients with PAH to determine timing for referral to a transplant centre.

-   Potentially eligible candidates should be referred for lung transplantation evaluation early, *i.e.* when they have an inadequate response to oral combination therapy, indicated by an intermediate or high risk according to the ESC/ERS risk stratification strategy or by a REVEAL risk score \>7.

-   Listing for lung transplantation should be considered in patients who present with a high risk of death according to the ESC/ERS risk stratification strategy or by a REVEAL risk score ≥10 despite receiving optimised medical therapy including *s.c.* or *i.v.* PCAs, as the expected mortality on medical therapy exceeds the expected mortality after bilateral lung transplantation. Depending on local circumstances, listing of patients at intermediate risk might be appropriate in some countries.

-   Timing of listing must depend on expected local waiting time.

-   Bilateral lung transplantation is the method of choice in patients with PH.

-   There is no degree of right ventricular dysfunction that precludes bilateral lung transplantation in patients with PAH.

-   Despite advances in ICU management and ECLS, the ideal recipient is an ambulant outpatient.

-   Extended use of ECMO support should be considered after lung transplantation in patients with PH to prevent early graft dysfunction.

-   Given the low number and high risk of lung transplants performed for PAH worldwide, this procedure should be concentrated in specialised centres.

Ethical considerations {#s8}
======================

Despite therapeutic progress, PAH remains a chronic, incurable and often fatal disease. Advanced ICU treatment including the use of ECLS is warranted whenever there is a clear treatment objective, be it recovery or transplantation. However, if these treatment goals are not realistically achievable, advanced intensive care will be futile and should be replaced by best supportive care, as should be the case in all patients who have reached the end of their life. It is important to consider the patient\'s preferences whenever possible and to proactively discuss end-of-life matters early on. Still, patients may change their perspectives once they are no longer in a stable situation but face imminent death.

Future perspectives {#s9}
===================

In the foreseeable future, PAH will remain an incurable, chronic and progressive disease. Reverse remodelling of the pulmonary vasculopathy is a main target of ongoing research, but success in human disease has been limited so far \[[@C72]\]. Hence, future studies should aim at developing new drugs to affect the disease itself, but also at developing new means to support the failing right ventricle. The development of (awake) ECMO as a bridge to transplantation has been a first step. Future devices will allow an extended use of extracorporeal or intracorporeal support systems, even in outpatients, like the use of left ventricular assist devices in patients with left-sided heart failure. It is impossible to foresee if or when such devices may obviate the need for lung transplantation. For the time being, lung transplantation remains an important treatment option for patients with otherwise refractory PAH.
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